Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ]: Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011
Mon, March 28, 2011
Sun, March 27, 2011
Fri, March 25, 2011
Thu, March 24, 2011
Wed, March 23, 2011
Tue, March 22, 2011
Mon, March 21, 2011
[ Mon, Mar 21st 2011 ]: Market Wire
30 p.m. ET

Medivation Announces Participation in Leerink Swann Cancer Roundtable Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. -leerink-swann-cancer-roundtable-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SAN FRANCISCO, CA--(Marketwire - March 31, 2011) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Cancer Roundtable Conference on Thursday, April 7, at 11:40 a.m. Eastern Time and participate in a panel discussion on prostate cancer at 12:15 p.m. Eastern Time at the Roosevelt Hotel in New York.

During the corporate presentation, Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.

A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at [ www.medivation.com ]. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at [ www.medivation.com ].